Author
@ResearchPulse1 ResearchPulse1
grade Bx.com/ResearchPulse1 ↗
Obsessive GLP-1/obesity-drug analyst who reads IQVIA scripts like tea leaves
Tracks the GLP-1/obesity pharma complex in near-real-time, s
trader score
+1.48
hit rate
40%
mean α
+0.52%
signals 14d
80
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 40% hit rate, +0.52% mean alpha, trader score +1.48. Their last-14d mentions, direction-adjusted, have moved -1.1% since posting (mean over 55 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | · | @ResearchPulse1 | · | Describes fill capacity, delayed filing and an expected January 2027 Wegovy PLUS launch, but omits issuer. | · | tweet ↗ |
| 2026-08-28 | · | @ResearchPulse1 | · | Quantifies Wegovy HD adoption, weekly growth and monthly prescription volume without naming issuer. | · | tweet ↗ |
| 2026-08-28 | · | @ResearchPulse1 | · | Argues oral obesity therapies will expand the market and forecasts stronger future oral amylin efficacy. | · | tweet ↗ |
| 2026-08-28 | VKTX | @ResearchPulse1 | +0.00 | Reports weekly GLP-1 prescription growth while questioning possible overreporting. | — | tweet ↗ |
| 2026-08-28 | LLY | @ResearchPulse1 | +0.20 | Reports weekly GLP-1 prescription growth while questioning possible overreporting. | — | tweet ↗ |
| 2026-08-28 | NVO | @ResearchPulse1 | +0.10 | Reports weekly GLP-1 prescription growth while questioning possible overreporting. | — | tweet ↗ |
| 2026-08-26 | LLY | @ResearchPulse1 | +0.05 | Reports NVO filing the Wegovy pill for China approval expected in 2027. | -1.2% | tweet ↗ |
| 2026-08-26 | VKTX | @ResearchPulse1 | +0.00 | Reports NVO filing the Wegovy pill for China approval expected in 2027. | -6.5% | tweet ↗ |
| 2026-08-26 | NVO | @ResearchPulse1 | +0.35 | Reports NVO filing the Wegovy pill for China approval expected in 2027. | -3.3% | tweet ↗ |
| 2026-08-26 | LLY | @ResearchPulse1 | +0.35 | Compares obesity-drug trial programs and expectations for GLP/GIP-amylin combinations. | -1.2% | tweet ↗ |
| 2026-08-26 | NVO | @ResearchPulse1 | +0.35 | Compares obesity-drug trial programs and expectations for GLP/GIP-amylin combinations. | -3.3% | tweet ↗ |
| 2026-08-26 | ABBV | @ResearchPulse1 | +0.45 | Argues mono-amylin drugs have superior tolerability and a large market, citing ABBV's $350M upfront deal. | -2.8% | tweet ↗ |
| 2026-08-26 | · | @ResearchPulse1 | · | Argues employers should bypass PBMs for GLP-1 drugs to cut costs and expand access. | · | tweet ↗ |
| 2026-08-26 | ABBV | @ResearchPulse1 | +0.45 | Argues low-GI amylins address GLP-1 discontinuation and cites ABBV-295's efficacy and monthly dosing. | -2.8% | tweet ↗ |
| 2026-08-25 | VKTX | @ResearchPulse1 | +0.00 | Gubra receives a $50M ABBV milestone as ABBV-295 enters Phase II obesity testing. | -5.9% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.